Advanced Clear-Cell RCC After Prior PD-(L)1 Therapy: When to Use Belzutifan–Lenvatinib vs VEGFR-TKI Sequencing

Authored by Open Medicine, published on 2026-06-01 02:58:33.0

This algorithm should help clinicians decide how to sequence systemic therapy for patients with unresectable locally advanced or metastatic clear-cell renal cell carcinoma after progression on prior anti–PD-(L)1 therapy. The practical clinical question is not simply “can belzutifan be used?” but rather: In which post–PD-(L)1 advanced ccRCC patients should belzutifan–lenvatinib be considered instead of cabozantinib or another VEGFR-TKI-based strategy? This should be a focused RCC sequencing algorithm, not a broad metastatic RCC pathway. It should specifically address the post–PD-(L)1 setting, where clinicians often need to choose among cabozantinib, belzutifan-containing therapy, other VEGFR-TKI strategies, clinical trial, or later-line belzutifan monotherapy when label criteria are met. Population and treatment-driving variables Target population: Adults with unresectable locally advanced or metastatic renal cell carcinoma with clear-cell component who have progressed after prior anti–PD-(L)1 therapy.

  1. Entry Criteria (ccRCC, progression after prior anti–PDL1)
    Unresectable locally advanced or metastatic RCC Clear-cell component Progression after prior anti–PD–(L)1 therapy
    • Prior therapy review
      Prior Therapy Review IO/TKI vs IO/IO Adjuvant IO relapse Prior VEGFR-TKI Prior lenvatinib / cabozantinib / belzutifan
      • Evaluate disease tempo, histology and risk factors
        Disease Tempo / Goal Indolent vs symptomatic progression Bulky / visceral / rapid disease Need for objective response? Sarcomatoid differentiation Brain metastases Oligoprogression
        • Fitness, safety and local access
          Fitness and safety considerations Hemoglobin and oxygen saturation Pulmonary risk Blood pressure and proteinuria Renal / hepatic / cardiovascular risk Local access Do you have monitoring capacity? Local access to Cabozantinib, Belzutifan or Lenvatinib?
          • Cabozantinib remains a standard option after prior IO therapy. Is the patient a good candidate for belzutifan–lenvatinib?
            To receive belzutifan–lenvatinib ensure: Access/reimbursement available Adequate performance status Acceptable blood counts Ability to tolerate lenvatinib toxicity No major concern regarding anemia/hypoxia Patient preference
            • YES (e.g. access, adequate performance status, no anemia/hypoxia concern, manageable len toxicity)
              What makes someone a good candidate? Access/reimbursement available Adequate performance status Acceptable blood counts Ability to tolerate lenvatinib toxicity No major concern regarding anemia/hypoxia Patient preference
              • Consider belzutifan + lenvatinib
                Evidence-supported option for selected post–PD-(L)1 advanced ccRCC Most useful when active disease control or response is needed Best suited if anemia / hypoxia risk is acceptable and VEGFR-TKI toxicity is manageable LITESPARK-011: improved PFS and ORR vs cabozantinib. However Belzutifan–lenvatinib is not necessarily a universal replacement for cabozantinib. Lenvatinib / VEGFR-TKI Monitoring: Blood pressure and proteinuria Renal and liver function Diarrhea, fatigue, appetite / weight loss Cardiac and bleeding risk
            • NO, not a good candidate for belzutifan–lenvatinib
              • Prior PD-(L)1 + VEGF-TKI exposure?
                • YES → Belzutifan monotherapy may be considered in patients previously treated with both PD-(L)1 therapy and a VEGF-TKI.
                  Distinct later-line setting Use if label / access criteria are met Do not conflate with belzutifan–lenvatinib combination use Belzutifan Monitoring: Baseline and periodic CBC / hemoglobin Baseline and periodic oxygen saturation Monitor dyspnea, fatigue, dizziness, syncope Follow prescribing information for dose holds / reductions / discontinuation Pregnancy / embryo-fetal toxicity counseling where relevant
                  • Further systemic therapy appropriate?
                    Poor systemic therapy candidate High competing morbidity Treatment burden outweighs benefit
                    • No → proceed with supportive / symptom-directed care
                    • YES → Continue evidence-based sequencing / clinical trial consideration
                • No → Cabozantinib or other VEGFR-TKI–based strategy preferred
                  • Appropriate when belzutifan–lenvatinib is not suitable • Especially relevant if anemia / hypoxia risk is high • Consider prior TKI exposure, comorbidities, and practicality
                  • Further systemic therapy appropriate?
                    Poor systemic therapy candidate High competing morbidity Treatment burden outweighs benefit
                    • No → proceed with supportive / symptom-directed care
                    • YES → Continue evidence-based sequencing / clinical trial consideration
  2. Evidence Anchor
    LITESPARK-011 phase 3 compared belzutifan + lenvatinib with cabozantinib in advanced clear-cell RCC after prior anti–PD-(L)1 therapy. The combination improved PFS and ORR; OS data were immature at interim analysis. Treatment selection should not rely solely on ORR/PFS advantages and should consider maturity of OS data.
  3. Editorial Caveats
    Belzutifan–lenvatinib is not a universal replacement for cabozantinib. Confirm local regulatory and guideline access. Belzutifan and lenvatinib are not interchangeable or equivalent clinical contexts.
  4. Consider clinical trial enrollment at any decision point
    Sequence uncertain Prior belzutifan exposure → clinical trial favored / expert review needed Prior lenvatinib or cabozantinib complicates selection Limited standard options
tosprivacy